10x Genomics Inc - Ordinary Shares - Class A
TXG
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.24B
Close$
$14.51
80.1% downside
Current Fair Value
80.1% downsideOvervalued by 80.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.24 Billion |
|---|---|
| Enterprise Value | $9.84 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.35 |
| Beta | 1.99 |
| Outstanding Shares | 129,984,169 |
Return
| Return on Equity | -9.10% |
|---|---|
| Return on Assets | -7.29% |
| Return on Invested Capital | -9.60% |
Valuation & Multiples
| P/E Ratio | -136.69 |
|---|---|
| PEG | 89.98 |
| Price to Sales | 18.28 |
| Price to Book Ratio | 12.18 |
| Enterprise Value to Revenue | 15.95 |
| Enterprise Value to EBIT | -112.48 |
| Enterprise Value to Net Income | -131 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$146.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$147.96 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 16.53% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.06%▼ 100.96% |
|---|---|
| Total Invested | $6.75M▼ 99.86% |
| Investors Holding | 10▼ 394.00% |
ESG Score
No data
About 10x Genomics Inc
CEO: Serge Saxonov